Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 20, 2026

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy.

Yakup Kordan1, Sam S Chang, Shady Salem

  • 1Department of Urologic Surgery and Biostatistics (SP), Vanderbilt University Medical Center, Nashville, Tennessee 37232-2765, USA.

The Journal of Urology
|September 18, 2009
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postmortem computed tomography and histopathology of distal limb lesions in giraffe (Giraffa spp.) under managed care.

PloS one·2026
Same author

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy.

BJU international·2026
Same author

Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-Muscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.

The Journal of urology·2026
Same author

Noninvasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Prospective Multisite Validation and Comparison with MRI.

The Journal of urology·2026
Same author

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026).

The Journal of urology·2026
Same author

Balancing Cure and Quality of Life: Navigating Functional Outcomes in Localized Prostate Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026

The 2002 TNM substages for pathological T2 prostate cancer do not predict biochemical recurrence-free survival in the intermediate term. Future staging systems may combine these substages due to lack of prognostic significance.

Area of Science:

  • Urology
  • Oncology
  • Pathology

Background:

  • Prostate cancer staging is crucial for treatment planning and prognosis.
  • The 2002 TNM staging system includes substages for pathological T2 (pT2) prostate cancer.
  • The prognostic value of these pT2 substages for intermediate-term outcomes requires evaluation.

Purpose of the Study:

  • To assess if the 2002 TNM substages of pathological T2 prostate cancer can predict intermediate-term biochemical recurrence-free survival after radical prostatectomy.

Main Methods:

  • Analysis of 1,370 patients with pT2 prostate cancer who underwent radical prostatectomy (2000-2008).
  • Comparison of clinical and pathological characteristics between pT2a, pT2b, and pT2c substages.
  • Kaplan-Meier analysis and Cox proportional hazards modeling to evaluate biochemical recurrence-free survival predictors.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Related Experiment Videos

Last Updated: Jun 20, 2026

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Main Results:

  • No significant difference in biochemical recurrence-free survival was observed between pT2 substages (p=0.174).
  • Predictors of recurrence included margin status, preoperative PSA, and Gleason score (p<0.001 for Gleason 8-10).
  • pT2b and pT2c substages did not predict recurrence compared to pT2a (p=0.99 and p=0.42, respectively).

Conclusions:

  • Current pT2 prostate cancer substages lack prognostic significance for intermediate-term outcomes.
  • Longer follow-up is needed to confirm these findings.
  • Future staging systems may consider consolidating pT2 substages into a single category.